BACKGROUND AND PURPOSE: @entity734 is a potential cause of @entity454 . Such @entity1 bear an elevated risk of developing @entity1606 . We report our experience with laparoscopic nephroureterectomy carried out in @entity1 with analgesic @entity8 to exclude upper urinary tract malignancy. All @entity1 were scheduled to be put on the waiting list for cadaveric renal transplantation. @entity1 AND METHODS: Since 1996, nine @entity1 and two @entity1 with a long-term history of analgesic abuse have undergone laparoscopic nephroureterectomy at our hospital. The median age was 63 years (range 51-70 years). All @entity1 had developed @entity454 secondary to heavy analgesic abuse with a median duration of 14 years (range 7-40 years). The median interval from the beginning of hemodialysis to laparoscopic nephroureterectomy was 36 months (range 6-76 months). RESULTS: The median operative time was 99 minutes (range 55-170 minutes). There were no conversions to open surgery. Two complications occurred, and three @entity1 required blood transfusions. The median hospital stay lasted 5 days (range 2-12 days), and the median convalescence was 20 days (range 6-44 days). In seven @entity1 , histopathologic examination of the kidney revealed changes attributable to analgesic abuse. None of the @entity1 had a @entity1606 , but in two @entity1 , a @entity1358 stage pT1cN0cM0 grade 2 was detected. CONCLUSION: @entity1 with analgesic @entity8 bear an elevated risk for the development of transitional-cell or @entity1358 . In these @entity1 , laparoscopic nephroureterectomy combines minimally operative invasiveness with a maximum of diagnostic safety.

Laparoscopic nephroureterectomy to exclude upper urinary tract malignancy associated with analgesic XXXX .

@entity1 :: ('9606', 'Species') :: ['women', 'Patients', 'patients', 'PATIENTS', 'men'] @entity8 :: ('MESH:D007674', 'Disease') :: ['nephropathy'] @entity1358 :: ('MESH:D002292', 'Disease') :: ['renal-cell carcinoma'] @entity1606 :: ('MESH:D002295', 'Disease') :: ['transitional-cell carcinoma', 'malignancies, predominantly transitional-cell carcinoma'] @entity734 :: ('MESH:D019966', 'Disease') :: ['Analgesic abuse'] @entity454 :: ('MESH:D007676', 'Disease') :: ['end-stage renal disease', 'end-stage renal failure']
@entity8 :: (MESH:D007674,Disease) :: ['nephropathy']
